New cocktail of drugs shows promise in hepatitis b trial

NCT ID NCT04225715

Completed Disease control Sponsor: Hoffmann-La Roche Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tested several new drug combinations in 281 people with chronic hepatitis B who were already on standard antiviral therapy. The goal was to see if adding experimental drugs could clear a key virus marker (HBsAg) from the blood. Participants received different combinations of oral and injected medications for up to 48 weeks, then were followed for another 48 weeks. The trial aimed to find safer and more effective ways to control the virus.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Combination of nucleoside analog (NUC), CpAM (Linvencorvir), TLR7 agonist (Ruzotolimod), siRNA (Xalnesiran), PEG-IFN (Pegasys), and PD-L1 LNA (Cadapersen)
What this could lead to: If successful, these combinations could help more people with chronic hepatitis B achieve a functional cure, meaning the virus is suppressed without lifelong medication.
What could go wrong: This is an early phase 2 trial with a small number of participants. The results may not apply to everyone, and some combinations may cause side effects or fail to show lasting benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic hepatitis B virus infection hepatitis B virus infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATITIS B CHRONIC

Contacts and locations

Locations

Asan Medical Center / Clinical Trial Center

Seoul, 138-736, South Korea
Auckland Clinical Studies Limited

Auckland, 1010, New Zealand
Beijing Friendship Hospital

Beijing, 100050, China
Changhua Christian Hospital

Chang-hua, 500, Taiwan
China Medical University Hospital

Taichung, 40447, Taiwan
Chuncheon Sacred Heart Hospital

Gangwon-Do, 200-704, South Korea
HIVNAT

Bangkok, 10330, Thailand
Hopital Beaujon

Clichy, 92118, France
Hospital Alvaro Cunqueiro

Vigo, Pontevedra, 36212, Spain
Hospital San Juan de Dios La Serena

La Serena, 1700000, Chile
Huashan Hospital, Fudan University

Shanghai, 200040, China
Kaohsiung Medical University Chung-Ho Memorial Hospital

Kaohsiung City, 807, Taiwan
King College Hospital NHS Foundation Trust

London, SE5 9RS, United Kingdom
Maharaj Nakorn Chiang Mai Hospital

Chiang Mai, 50200, Thailand
Middlemore Clinical Trials

Auckland, New Zealand
Nanfang Hospital, Southern Medical University

Guangzhou, 510515, China
National Cheng Kung Univ Hosp

Tainan, 00704, Taiwan
National Taiwan University Hospital

Taipei, 10002, Taiwan
Queen Mary Hospital

Hong Kong, Hong Kong
Ruijin Hospital Shanghai Jiaotong University School of Medicine

Shanghai, 200025, China
SMG-SNU Boramae Medical Center

Seoul, 156-707, South Korea
Seoul National University College of Medicine, Liver Research Institute

Seoul, South Korea
Siriraj Hospital

Bangkok, 10700, Thailand
Spitalul Clinic Judetean de Urgenta Cluj Napoca

Cluj-Napoca, 400006, Romania
Taichung Veterans General Hospital

Taichung, 40705, Taiwan
The First Hospital of Jilin University

Changchun, 130021, China
Tokuda Hospital Sofia

Sofia, 1407, Bulgaria
Toronto Liver Centre

Toronto, Ontario, M6H 3M1, Canada
Uni of Alberta Hospital

Edmonton, Alberta, T6G 2S2, Canada
University Multiprofile Hospital For Active Treatment "Sveti Ivan Rilski" EAD

Sofia, 1431, Bulgaria
University of Calgary

Calgary, Alberta, T2N 2T9, Canada
Vall d?Hebron Institute of Oncology (VHIO), Barcelona

Barcelona, 08035, Spain
West China Hospital, Sichuan University

Chengdu, 610041, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.